Drug Trial Radar · NCT04000594
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Sep 2, 2019
Primary completion
Jan 18, 2022
Study completion Jan 18, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response to RO7234292 (RG6042) treatment after intrathecal (IT) administration of RO7234292 (RG6042) to patients with manifest Hungtington's disease (HD).
Conditions
- Huntingtons Disease
Interventions
RO7234292 (RG6042)Drug
RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concentrations of RO7234292 in CSF (Cerebrospinal Fluid)Time frame: Day 1, 2, 3, 4, 29, 43, 71, 127, and follow-up visit (6 months after last study drug administration)
- Concentrations of RO7234292 in PlasmaTime frame: Day 1, 2, 3, 4, 5, 28, 29, 30, 43, 71, 127, and follow-up visit (6 months after last study drug administration)
- mHTT (Mutant Huntingtin) Concentration in CSFTime frame: Days 1, 2, 3, 29, 43, 71, 127 and follow-up visit (6 months after last study drug administration)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Centre For Human Drug Research; Research
Leiden, Netherlands
Leonard Wolfson Experimental Neurology Centre
London, United Kingdom
Manchester University NHS Foundation Trust (MFT)
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.